SLC5A2 and atherosclerosis: In addition to the insulin-independent reduction in high glucose, SGLT2 inhibitors improve risk factors for CVD, such as body weight, systolic blood pressure, uric acid, and lipid profile, and potentially protect against the pathogenesis of atherosclerosis [260].